Tissue Regeneration Technologies Announces Former Senator Max Cleland as Senior Policy Advisor

Business Wire, July 27, 2007

WOODSTOCK, Ga. -- Tissue Regeneration Technologies (TRT) will announce Monday that Former United States Senator Max Cleland has joined the firm as its Senior Policy Advisor. Senator Cleland's primary role will be to serve as the company's liaison to both the government and healthcare communities on behalf of its advanced wound and cardiac care technology. TRT is currently sponsoring clinical trials to treat wounded US soldiers returning from combat in Iraq and Afghanistan.

Senator Cleland, who served in the United State Senate (1996-2002) and previously had been appointed by President Jimmy Carter as Administrator of the United States Veterans Administration (1977-1981), is a long-time advocate for veterans issues. Sen. Cleland also served in the Georgia state senate from 1971 to 1975 and for 12 years as the Georgia Secretary of State. A veteran himself, Senator Cleland served in the US Army from 1965 to 1968, attaining the rank of captain. He was awarded the Silver Star and the Bronze Star for valorous action in combat in Vietnam.

"Throughout his career in public service, Senator Cleland has worked tirelessly to improve the quality of healthcare for our troops. With this same goal in mind, TRT is very fortunate to have him advocate our wound care technology to benefit those who so desperately need it; namely those wounded soldiers returning from overseas combat and injured veterans," stated John Warlick, TRT's President and CEO.

"Based on our research on diabetic foot ulcers and other wounds, we believe our technology will prevent numerous amputations on veterans and greatly speed the recovery time for certain combat injuries, including those sustained from Improvised Explosive Devices, (IED's)," Warlick continued. "In many cases, our technology has been shown to not only greatly reduce scar tissue but also generate new, healthy tissue, especially in burn patients."

TRT is currently involved in the Combat Wound Initiative (CWI) underway at Walter Reed Army Medical Center. The CWI is a randomized clinical trial designed to study the effectiveness of TRT's ground-breaking MultiWave[TM] technology on soft tissue and bone injuries sustained by American soldiers through the combined effects of blast, penetrating fragment, and burns from IED's. Additionally, through its cardiac subsidiary, Cardiac Regeneration Technologies (CRT), the company is the world's leader in shockwave research for the treatment of ischemic heart disease. CRT's animal research suggests that damaged hearts can regain near normal function in as little as 12 weeks.

"We will be working diligently on behalf of our men and women in uniform to advance this innovative technology into the military arena. I believe it will greatly benefit our soldiers and veterans. Our soldiers deserve the best and I am very proud to be part of this truly worthy endeavor," stated Cleland.

About TRT

TRT is a leading-edge healthcare company that believes in "doing well by doing good." Our state-of-the-art medical devices utilize MultiWave(TM) technology (a combination of heat, electromagnetic, acoustic, and light energies: h-e-a-l) to provide non-invasive and minimally invasive treatment for numerous pathological conditions, including chronic wounds, multiple periodontal applications, pseudoarthrosis and other avascular conditions of the bone, and ischemic heart disease. TRT is headquartered in suburban Atlanta, Georgia from which we operate our urology division, Shockwave Technical Service, and our cardiac subsidiary, Cardiac Regeneration Technologies. Production of our devices is handled by TRT's manufacturing subsidiary, MTS Europe GmbH, located in Lake Constance, Germany.

TRT is currently conducting FDA trials with its DermaGold[TM] MultiWave[TM] device for the treatment of wounds as well as plantar fasciitis. TRT has FDA clearance to market its LithoGold(TM) lithotripsy system for treatment of kidney and ureteral stones. Our devices are currently CE approved and distributed in approximately 20 countries throughout North America, Europe, Asia, Africa and South America. For more information, please visit the company's website at www.trtllc.com.

Note: Senator Cleland will be available for print and television interviews at 2:00 p.m. on Monday, July 31st at TRT's global headquarters located at 110 Arnold Mill Park, Suite 400, Woodstock, Georgia 30188. For any reporters on deadline prior to this date, please contact:

TRT - John Warlick, (404) 402-6844 / jwarlick@trtllc.com

Fmr. Senator Cleland - Michael Duga, (561) 929-2600 / Duga@1stcounsel.com